Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

RELEVIUM Improving quality of life of advanced pancreatic cancer patients through an AI-guided multimodal intervention, combining pain and cachexia management, nutrition, and physical activity

Coordinator
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Germany
Runs
1 September 2022 to 30 November 2026
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
19 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101057821

What the project is doing

In the project's own words, from its summary on CORDIS.

Pancreatic cancer has the lowest survival rate amongst other cancers and is responsible for 95,000 deaths every year in the EU. Its treatment is usually palliative, aiming at slowing tumour progression and at symptom management. The main hypothesis of RELEVIUM is that quality of life (QoL) of advanced pancreatic cancer patients can be significantly improved by reducing pain and cachexia through highly personalised nutrition, physical activity, and pain management strategies, in addition to chemotherapy treatment.

To achieve this, RELEVIUM will empower patients with digital tools that facilitate patient-doctor communication and enable them to self-manage their disease. RELEVIUM will use (i) a multi-sensor smartwatch and an innovative remote ultrasound patch, (ii) AI algorithms for continuous remote monitoring of pain and sarcopenia, as well as for decision support, and (iii) patient and caregiver applications. Combined, these tools will provide a stream of evidence on symptom progression and will enable physicians to apply personalised care plans.

RELEVIUM brings together an interdisciplinary team of experts and will also involve patients and their caregivers in an iterative co-creation process. The project will initially conduct a feasibility and data collection study (RELEVIUM-FDC, n=130). The study aims at optimizing patient adherence and compliance, and at collecting data for the development of the intervention. A five-centre randomized clinical trial (RELEVIUM-RCT) will then evaluate the efficacy of the proposed personalised care plans for advanced pancreatic cancer patients (n=132) in terms of their QoL.

Several secondary outcomes will be investigated, such as the cost-effectiveness of the intervention, its potential in increasing health equity and in relieving the stress burden on the patient families. The study outcomes will result in recommendations for integrating remote monitoring and improving QoL outcomes in palliative care for advanced pancreatic cancer

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyCoordinator
Ainigma TechnologiesLeuvenBelgiumParticipant
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumParticipant
European Cancer Patient CoalitionBruxelles / BrusselBelgiumParticipant
Pulsify Medical BVLeuvenBelgiumParticipant
Rosenbaum ConsultingSofiaBulgariaParticipant
Csi Center for Social Innovation LtdNicosiaCyprusParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Johannes Gutenberg-Universitat MainzMainzGermanyParticipant
Mcs DatalabsBerlinGermanyParticipant
Sihtasutus Pohja-Eesti RegionaalhaiglaTallinnEstoniaParticipant
Charokopeio PanepistimioAthinaGreeceParticipant
Diadikasia Business Consulting Symvouloi Epicheiriseon AeAthinaGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Exus Software Monoprosopi Etairia Periorismenis EvthinisAthinaGreeceParticipant
Futuro Perfecto Innovacion SLMadridSpainParticipant
Institut CurieParisFranceParticipant
The Health Corporation - RambamHaifaIsraelParticipant
Stichting European Nutrition for Health AllianceAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI